Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.

ABSTRACT:

Objective

Natalizumab is a humanized recombinant monoclonal antibody against very late activation antigen-4 approved for the treatment of patients with multiple sclerosis (MS). A phase II study failed to demonstrate a difference between natalizumab treatment groups and the placebo group with regard to gadolinium enhancing lesions on MRI 3 months after discontinuation of therapy. The objective of this study was to assess clinical MS disease activity, surrogate disease markers on MRI, immunologic parameters in peripheral blood and CSF, as well as safety in patients with MS after discontinuation of natalizumab therapy.

Methods

This study is a longitudinal and serial cross-sectional assessment, in which 23 patients who were treated with natalizumab in the context of two phase II

SUBMITTER: Stuve O 

PROVIDER: S-EPMC2677530 | biostudies-literature | 2009 Feb

REPOSITORIES: biostudies-literature